Nattokinase is an enzyme associated with natto, a Japanese food made from fermented soybeans. Human research suggests it can influence some blood-clotting measurements, and small trials have reported blood-pressure benefits. Those findings do not establish that a supplement safely dissolves a dangerous clot or removes calcium from artery walls.
The distinction matters because the two popular claims describe different problems. A clot is a mass formed from components of blood. Calcium in an artery is part of a process occurring within the vessel wall. Evidence concerning one does not demonstrate an effect on the other.
Where nattokinase comes from
During natto production, bacteria ferment cooked soybeans and produce enzymes, including nattokinase. An enzyme is a protein that helps a particular chemical reaction occur. Natto has a sticky texture and strong flavor, while a nattokinase supplement is a concentrated preparation sold in a different form.
The food and the capsule should not be treated as interchangeable. A food serving contains a mixture of nutrients and fermentation products. A trial of an isolated enzyme preparation tests that preparation, under its particular conditions. It cannot tell us that an ordinary portion of fermented soybeans reproduces the same exposure.
Natto can fit a vegan diet. Ready-made sauces and capsule shells still deserve a label check, since accompanying ingredients vary. Soy allergy is also relevant. A plant origin does not remove the need to consider allergies, formulation or interactions.
What does clot breakdown mean?
Fibrin is a protein that forms a mesh within a blood clot. Fibrinolysis means breaking down that mesh. Researchers can study this process in a laboratory and measure substances in blood that change when fibrin is broken down.
The body needs a balance between forming clots and breaking them down. Clotting helps stop bleeding after an injury. A clot forming in the wrong place can obstruct blood flow. An intervention affecting this balance can therefore create both a potential research opportunity and a reason for caution.
The word fibrinolytic describes an activity, not a guarantee of a clinical result. Seeing an enzyme act on material in a dish is an early step. Showing that swallowing it improves outcomes in patients with a diagnosed clot is a much more demanding question.
The small human study behind many claims
A 2015 single-dose crossover study (https://pubmed.ncbi.nlm.nih.gov/26109079/) tested nattokinase and placebo in 12 healthy young men. In a crossover design, the same volunteers receive both interventions at separate times. Researchers followed clotting and clot-breakdown markers for eight hours after a studied 2,000-FU preparation.
Some markers changed, including D-dimer, a substance associated with fibrin breakdown, and measures involved in coagulation. Values remained within normal ranges. The volunteers did not have dangerous clots requiring treatment. The experiment therefore showed a short-term biological signal, without showing that nattokinase cleared an obstructed vein or prevented a stroke.
The paper's full results (https://pmc.ncbi.nlm.nih.gov/articles/PMC4479826/) help keep its title in perspective. A word such as thrombolysis can sound like evidence of emergency clot removal, but the actual participants and measurements define what was demonstrated.
Why a blood test cannot prove a clot disappeared
Imagine a study that detects more fragments of a material after an intervention. That tells researchers something about turnover of that material. It does not identify a particular dangerous blockage, measure whether blood flow returned or establish that the patient recovered safely.
A clinical clot-treatment study would need diagnosed patients, an appropriate comparison, defined imaging or clinical outcomes and careful bleeding surveillance. Researchers would also need to examine whether events recur. Those questions cannot be answered by a few hours of blood tests in healthy volunteers.
For the same reason, checking a clot-related blood marker yourself cannot establish that a supplement is working. Such results depend on clinical context. A number that rises after a supplement should not be interpreted as proof that unwanted clots are being cleared.
Does nattokinase remove artery calcium?
The phrase scrapes calcium off artery walls gives a misleading picture of the biology. Atherosclerotic plaque develops within artery walls and can contain fats, inflammatory cells, fibrous tissue and calcium. It is not simply loose scale waiting for an enzyme to wash it away.
The National Heart, Lung, and Blood Institute's explanation of atherosclerosis (https://www.nhlbi.nih.gov/health/atherosclerosis) describes this plaque process. Evidence for a claim about coronary calcium would need appropriate imaging of calcium in the coronary arteries, which supply the heart. A clotting test does not measure that.
An ultrasound measurement in the carotid arteries of the neck also answers a different question from a coronary calcium scan. A study may be worth discussing while still failing to test the advertised claim. Calling every change in an artery measurement decalcification makes the evidence sound more specific than it is.
The encouraging observational artery study
A 2022 clinical report examined records from 1,062 people with abnormal blood fats (https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.964977/full). It reported improvements in blood fats and carotid ultrasound measurements after 12 months of nattokinase use. The main reported regimen was 10,800 FU daily, a research exposure rather than a personal dosing recommendation.
This was a retrospective study, meaning researchers looked back at existing records. It was not a randomized placebo-controlled trial. Lifestyle differences, other treatments, participant selection and measurement issues could influence the results. The findings justify a better controlled investigation, but they cannot demonstrate that nattokinase caused all the observed changes.
The report did not establish that a supplement physically removed coronary calcium. Its size does not solve that mismatch: a large study of one measurement remains a study of that measurement.
A longer randomized trial found no artery benefit
The 2021 Nattokinase Atherothrombotic Prevention Study (https://pubmed.ncbi.nlm.nih.gov/33843667/) randomly assigned 265 adults without clinical cardiovascular disease to nattokinase or placebo. Their median age was about 65. Researchers used repeat carotid ultrasound and followed participants for a median of three years.
At the tested 2,000-FU exposure, nattokinase did not significantly improve the progression of artery-wall thickness or stiffness compared with placebo. The trial also found no significant benefit in the measured blood pressure or laboratory outcomes.
These participants were relatively healthy and at low cardiovascular risk. The result cannot rule out every possible effect in another population or with another preparation. It does, however, prevent an honest account from presenting artery improvement as an established or consistent finding. Increasing the dose on your own is not a justified response to a negative trial.
Blood-pressure research offers a narrower possibility
A 2008 randomized trial (https://pubmed.ncbi.nlm.nih.gov/18971533/) enrolled 86 people with elevated untreated blood pressure; 73 completed the eight-week protocol. Compared with placebo, the nattokinase group had average net reductions of about 5.6 mmHg in the upper blood-pressure number and 2.8 mmHg in the lower number.
That is an encouraging finding for a specific question. Eight weeks of blood-pressure measurements cannot establish fewer heart attacks over several years. It also does not resolve why the longer prevention trial found no blood-pressure effect. Different participants, study designs and preparations need to be considered.
A person with raised readings needs those readings interpreted over time. The supplement literature does not provide a basis for stopping prescribed treatment, or for choosing a capsule without reviewing medicines and health history.
Bleeding risk deserves practical attention
An effect on clotting is relevant to safety even when a product is sold without a prescription. People taking anticoagulant or antiplatelet medicines, people with bleeding disorders and those preparing for an operation should discuss nattokinase with their clinician or pharmacist before use.
A published case report describes severe abdominal bleeding in an older woman taking nattokinase (https://pubmed.ncbi.nlm.nih.gov/35003944/). The amount taken was uncertain, and a single case cannot establish the risk at an ordinary labeled exposure or prove that the supplement alone caused the outcome. It is a safety signal, not a calculation of how often bleeding occurs.
Do not combine several products advertised as blood thinners on the assumption that natural ingredients cannot interact. Bring the actual labels to a medication review. The brand name alone may not identify the enzyme activity, additional ingredients or capsule contents.
Natto, vitamin K and medicine use
Whole natto also raises a separate question for people taking warfarin because of its vitamin K content. Warfarin treatment depends partly on consistent vitamin K intake. A nattokinase capsule may have a different composition from the food, and that difference needs checking rather than guessing.
The NHS guidance on warfarin and food (https://www.cuh.nhs.uk/patient-information/dietary-advice-for-patients-taking-warfarin/) explains why sudden dietary changes matter. Ask about the specific product and medicine together. Replacing a prescribed anticoagulant with fermented food or an enzyme supplement can leave the original medical problem untreated.
When symptoms need urgent assessment
Sudden breathlessness, chest pain, coughing blood or a newly swollen painful leg can be signs of a serious clot. Sudden face drooping, arm weakness or speech difficulty can signal stroke. Seek urgent medical care rather than waiting for a supplement to act. The NHS overview of blood clots (https://www.nhs.uk/conditions/blood-clots/) explains these warning signs.
Nattokinase remains an interesting subject for research into clotting biology and cardiovascular risk markers. Its strongest marketing promises require evidence the available studies do not provide. Readers considering it should discuss a defined goal and the bleeding context, while keeping dangerous clots and artery-calcium claims firmly separate.
30 Reddit comments: reader experiences and questions
These are paraphrases of 30 distinct public comments, collected on 20 November 2026. Each source link opens the original discussion. Usernames and relative dates are reproduced as displayed in the retrieved page; exact posting dates were not consistently available. These are unverified anecdotes and questions, not medical evidence or instructions. Some comments contain unsupported claims, multiple treatments or uncertain product identity. They are a qualitative sample, not a poll or an estimate of how often benefits or harms occur.
- eezyduzit, displayed 2y ago: Claimed artery and clot benefits while describing several enzymes and slower bleeding cessation.
- EMDEELOWKEY, displayed 2y ago: Reported using multiple enzymes and planning a cardiology visit.
- Ok_Result5965, displayed 2y ago: Asked about brand reliability after a reported ownership change.
- eezyduzit, displayed 2y ago: Could not verify the ownership concern and wondered about alternatives.
- everyeargiants, displayed 2y ago: Reported high blood-pressure readings and emergency assessment after taking a product.
- Annual_Potential_439, displayed 1y ago: Discussed switching products and combining several supplements.
- C0ffeeface, displayed 2y ago: Raised possible differences between enzymes, without recalling the source.
- Zebrakd, displayed 2y ago: Asked how a suspected clot had actually been diagnosed.
- eezyduzit, displayed 2y ago: Raised bleeding and medicine-interaction concerns.
- balanced_views, displayed 2y ago: Interpreted an adverse reaction as clot clearance; that explanation is unsupported.
- PierreDoowah, displayed 1y ago: Asked what symptoms occurred during the reported adverse reaction.
- Outrageous_Tree_3962, displayed 10mo ago: Also requested details of the adverse experience.
- Physical_Gold_1485, displayed 2y ago: Reported a substantial benefit without describing an objective measurement.
- Ok_Tap6569, displayed 1y ago: Warned against replacing prescribed anticoagulation and described unverified family losses.
- Outrageous_Tree_3962, displayed 10mo ago: Disputed attributing outcomes to a single change; no medical records were provided.
- I_Adore_Everything, displayed 2y ago: Asked whether calcium scans or other tests documented the claimed plaque reduction.
- Zebrakd, displayed 2y ago: Suggested diagnostic assessment rather than assuming leg symptoms meant a clot.
- Zebrakd, displayed 2y ago: Described a personal history of medically investigated clots and follow-up.
- Outrageous_Tree_3962, displayed 10mo ago: Preferred nattokinase to prescribed medicine based on personal beliefs about side effects.
- Iggy_Arbuckle, displayed 2y ago: Suggested changing intake based on a research interpretation; this is not dosing advice.
- __lexy, displayed 2y ago: Expressed confidence without giving supporting details.
- donutsfordoge, displayed 2y ago: Reported strong benefit without specifying the outcome.
- Zebrakd, displayed 2y ago: Questioned confusion between blood clots and artery plaque.
- 3sCompanyAficionado, displayed 2y ago: Disputed that nattokinase was expensive.
- RealTelstar, displayed 2y ago: Argued that cost depends on the amount taken; the proposed amount is not validated here.
- 3sCompanyAficionado, displayed 2y ago: Questioned how supplement intake compares with enzyme content in food.
- largececelia, displayed 2y ago: Reported a bad reaction and urged caution.
- PartHerePartThere, displayed 2y ago: Described a changing palm lump while using an enzyme combination; diagnosis was unclear.
- BoredAccountant, displayed 2y ago: Discussed fermenting soybeans and whether the food's texture and flavor would appeal.
- No-Lobster-9275, displayed 3mo ago: Reported improved longstanding foot color and sensation after starting nattokinase.
Author and editorial background
Bob Vaughan aka Healthy Mango has studied alternative medicine for around 30 years, with homeopathy certification obtained in India and certifications in yoga and Faster EFT. He has also studied Arthur Janov's Primal Therapy and received Primal Therapy at the Janov center in Los Angeles. These are owner-supplied biographical details, not medical credentials or evidence that a treatment works. Read the full author background.
Alternative & Complementary Medicine has published on these topics since January 2005, more than 20 years ago. Its original announcement records that history. This article links to research and explains its limits. AI assisted with research organization and drafting. No qualified medical review is claimed. Readers can send corrections through the contact page.




